北京科锐国际人力资源股份有限公司 内部审计管理制度 第一章 总 则 第一条 为进一步规范对北京科锐国际人力资源股份有限公司（以下简称"公 司"）、控股子公司的内部审计工作，提高内部审计工作质量，保护投资者的合法 权益，根据《中华人民共和国公司法》《中华人民共和国证券法》《中华人民共和 国审计法》《审计署关于内部审计工作的规定》《深圳证券交易所创业板股票上市 规则》《深圳证券交易所上市公司自律监管指引第2号——创业板上市公司规范运 作》《企业内部控制基本规范》《上市公司治理准则》等有关法律、法规、规章和 《北京科锐国际人力资源股份有限公司章程》（以下简称"《公司章程》"）的规定， 结合公司实际情况，制定本制度。 第二条 本制度适用于对公司各内部机构、控股子公司以及具有重大影响的 参股公司的与财务报告和信息披露事务相关的所有业务环节所进行的内部审计 工作。 第三条 本制度所称内部审计，是指公司内部审计机构或人员依据国家有关 法律法规和本制度的规定，对公司各内部机构、控股子公司的内部控制和风险管 理的有效性、财务信息的真实性、完整性以及经营活动的效率和效果等开展的一 种评价活动。 第四条 本制度所称内部控制，是指由 ...

北京科锐国际人力资源股份有限公司 媒体采访和投资者调研接待办法 第一条 为贯彻证券市场公开、公平、公正原则，规范北京科锐国际人力 资源股份有限公司（以下简称"公司"）的媒体采访和投资者调研接待行为， 加强公司与媒体、投资者的沟通与交流，提高公司的投资者关系管理水平，根 据《中华人民共和国公司法》《中华人民共和国证券法》，深圳证券交易所发 布的《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律 监管指引第2号——创业板上市公司规范运作》等法律、法规、规范性文件及《 北京科锐国际人力资源股份有限公司章程》的规定，结合公司实际情况，制订 本办法。 第二条 本办法所述的媒体采访和投资者调研接待工作，是指公司通过接 受投资者、媒体、证券机构的调研、一对一的沟通、现场参观、分析师会议、 路演和业绩说明会、新闻采访等活动，增进投资者对公司的了解和价值认同的 工作。 第三条 制定本办法的目的在于规范公司在接受调研、采访、沟通或进行 对外宣传、推广等活动时，增加公司信息披露的透明度及公平性，改善公司治 理结构，增进资本市场对公司的了解和支持。 第四条 本办法所称重大信息是指对公司股票及其衍生品种交易价格可能 或已 ...

北京科锐国际人力资源股份有限公司 薪酬与考核委员会工作规则 第一章 总则 第一条 为规范北京科锐国际人力资源股份有限公司(以下简称"公司") 董事会决策机制，完善公司治理结构，根据《中华人民共和国公司法》《中华人 民共和国证券法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上 市公司自律监管指引第2号——创业板上市公司规范运作》等法律、法规、规章、 规范性文件及《北京科锐国际人力资源股份有限公司章程》(以下简称"《公司 章程》")的有关规定，公司特设立董事会薪酬与考核委员会(以下简称"本委员 会"),并制定本工作规则。 第二条 本委员会是董事会设立的专门工作机构，主要负责制定公司董事及 高级管理人员的考核标准并进行考核；负责制定、审查公司董事及高级管理人员 的薪酬政策和方案，向董事会负责。 第三条 本工作规则所称高级管理人员是指公司的总经理、副总经理、董事 会秘书、财务总监。 第二章 人员组成 第四条 本委员会成员由三名董事组成，其中独立董事应占多数。 第六条 选举委员的提案获得通过后，新任委员在董事会会议结束后立即就 任。 第七条 本委员会设主任委员（召集人）一名，由独立董事委员担任，负责 主持委员 ...

北京科锐国际人力资源股份有限公司 年报信息披露重大差错责任追究制度 第一章 总则 第一条 为提高规范北京科锐国际人力资源股份有限公司（以下简称"公司"） 规范运作水平，增强年度报告信息（以下简称"年报信息"）披露的真实性、准确 性、完整性和及时性，加大对年报信息披露责任人的问责力度，提高年报信息披露 的质量和透明度，根据《中华人民共和国公司法》《中华人民共和国证券法》（以 下简称"《证券法》"）中国证券监督管理委员会（以下简称"中国证监会"）发 布的《上市公司信息披露管理办法》等相关法律、法规、规范性文件及《北京科锐 国际人力资源股份有限公司章程》（以下简称"《公司章程》"）、公司《信息披 露管理制度》等，结合公司实际情况，制定本制度。 第二条 公司有关人员应当严格执行《中华人民共和国会计法》《企业会计准 则》及其他相关规定，遵守公司与财务报告相关的内部控制制度，确保财务报告 真实、公允地反映公司的财务状况、经营成果和现金流量。 公司任何人员不得干扰、阻碍公司聘请的会计师事务所及注册会计师独立、 客观地进行年报审计工作。 第三条 本制度所指的责任追究，是指年报信息披露工作中有关人员不履 行或者不正确履行职责、 ...

Group 1 - The core viewpoint of the announcement is that the company reported significant growth in both revenue and net profit for the first half of 2025, indicating strong operational performance [1] Group 2 - The company's operating revenue for the first half of 2025 reached 7.075 billion yuan, representing a year-on-year increase of 27.67% [1] - The net profit for the same period was 127 million yuan, showing a year-on-year growth of 46.96% [1]

北京科锐国际人力资源股份有限公司 2025 年半年度报告全文 北京科锐国际人力资源股份有限公司 2025 年半年度报告 2025-043 2025 年 8 月 28 日 1 北京科锐国际人力资源股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人高勇、主管会计工作负责人尤婷婷及会计机构负责人(会计主 管人员)赵思瑶声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 1、宏观经济波动风险 当前世界经济复苏动能不足，外部环境复杂性严峻性不确定性明显上升， 国内有效需求仍显不足，经济运行出现分化，结构调整持续深化等带来新挑 战，就业总量压力不减，结构性矛盾仍待破解。这一系列的内外部因素可能 导致企业招聘需求景气度下降，从而对企业发展扩张和人员招聘需求造成一 定的不良影响。同时，公司海外市场收入占比较大，受全球经济环境不确定 性、地缘政治、贸易摩擦等因素的影响，国际经济环境变动可能对公 ...

Investment Rating - The report maintains an "Outperform" rating for the social services sector, indicating expected performance above the market index by over 10% [4][32]. Core Views - The social services sector is anticipated to benefit from favorable government policies aimed at expanding domestic demand, leading to a potential valuation recovery during the reporting period [4][32]. - The consumer services sector saw a rise of 5.18% during the reporting period, although it underperformed the broader market by 1.47 percentage points [13][15]. Summary by Sections Sector Review - The consumer services sector's performance from August 11 to August 24, 2025, included notable stock increases for companies such as Kede Education (39.74%), Dongfang Zhenxuan (22.88%), and Huazhu Group-S (12.91) [15][16]. - Conversely, stocks like Keri International (-7.52%) and New Macau International Development (-5.84%) experienced significant declines [15][16]. Industry and Company Dynamics - Companies like Dou Shen Education and Fenbi have launched new AI-driven educational products to enhance learning experiences [17][18]. - NetEase Youdao introduced several AI education products, including an upgraded Q&A pen and a comprehensive listening device, further developing its AI education ecosystem [19]. - The Supreme Court's new regulation effective September 1 invalidates any agreements to not pay social security, allowing workers to seek economic compensation [20]. Stockholding Analysis - During the reporting period, significant changes in stockholding proportions were noted, with Hai Di Lao increasing by 0.84 percentage points to 21.54% and Tianli International Holdings increasing by 3.43 percentage points to 56.95% [29][3]. Investment Recommendations - The report suggests a focus on companies such as Atour, Ctrip Group-S, Xiaocaiyuan, and BOSS Zhipin, among others, for potential investment opportunities [4][32]. - Mid-term recommendations include companies like China Duty Free, Meituan-W, and Huazhu Group-S, indicating a broad range of investment options within the sector [4][32].

Core Viewpoint - The pharmaceutical industry is transitioning towards a "small but refined" recruitment strategy, reflecting a shift from aggressive expansion to a focus on quality and efficiency in response to market challenges [1][4][5]. Recruitment Trends - Overall recruitment in the pharmaceutical sector has not shown significant recovery, with a reduction in hiring levels [1][4]. - Companies are adopting a more cautious approach, leading to increased demand for specific roles and levels [4][5]. - 43% of surveyed companies reported stable recruitment compared to the previous year, while 33% indicated a decline in hiring [5]. Salary Expectations - There has been a notable decrease in salary expectations among industry professionals, with the anticipated increase dropping from 20%-30% to 10%-20% [4][9]. - The phenomenon of accepting lower salaries for suitable opportunities has emerged, indicating a shift in job-seeker priorities [4][9]. Job Role Demand - Demand for traditional support roles and general pharmaceutical representatives is declining, while specialized roles such as academic representatives and human resource managers remain in high demand [7]. - There is a growing need for talent in innovation, operational efficiency, and regulatory compliance, including new drug development and digitalization [7][10]. Employment Environment - The financing environment for pharmaceutical companies has worsened, leading to a more pragmatic approach to hiring and potential layoffs [10]. - The tightening profit margins due to price controls have reduced the incentive for hiring, as new personnel may not yield proportional profit increases [10]. New Graduate Employment - Despite an apparent oversupply of graduates in pharmaceutical fields, there is a disconnect between their skills and market needs, prompting companies to reduce campus recruitment [10][11]. - Recommendations for graduates include pursuing passion in their field, gaining practical experience, and maintaining a commitment to lifelong learning [11]. Flexible Employment Trends - An increasing number of pharmaceutical companies are adopting flexible employment models, such as outsourcing and project-based hiring, to enhance operational efficiency and reduce costs [12][13]. Human Resource Service Adaptation - Human resource service providers need to remain sensitive to market changes, improve operational efficiency through AI, and adapt to the trend of flexible employment [14]. - Companies like 科锐国际 are already engaging a significant number of flexible workers to meet diverse client needs [14]. Future Outlook - The "small but refined" recruitment trend is expected to persist as the pharmaceutical industry shifts from generic drugs to innovative original drugs, making it a strategic choice for optimizing operations in the short term [15].

Core Insights - The pharmaceutical industry is experiencing a shift from aggressive expansion to a focus on quality and efficiency, as companies adapt to a challenging market environment characterized by increased financing difficulties and price controls [2][4][8] - A recent survey indicates that pharmaceutical companies are adopting a "small but precise" recruitment strategy, with a focus on specific roles and expertise rather than broad hiring [5][6][12] Recruitment Trends - Overall recruitment in the pharmaceutical sector is declining, with 43% of companies reporting stable hiring compared to last year, and 33% indicating a decrease in recruitment [5][8] - The demand for traditional roles, such as general pharmaceutical representatives, is decreasing, while there is a strong demand for specialized roles, including those in new drug development and digitalization [6][8] Employee Sentiment - Pharmaceutical professionals are increasingly seeking job stability, with salary expectations dropping from 20%-30% to 10%-20% for job changes, and some are even willing to accept lower salaries for more stable positions [3][7] - The trend of accepting lower salaries for suitable opportunities is becoming more common among industry professionals [3][7] Market Dynamics - The financing environment for pharmaceutical companies has worsened since 2023, leading to more cautious hiring practices and even layoffs in some cases [8][12] - The tightening profit margins due to stricter price controls have reduced the incentive for companies to hire new staff, as the marginal benefits of new hires have diminished [8][12] New Graduate Employment - There is a perceived oversupply of new graduates in the pharmaceutical field, but a disconnect exists between their academic training and the practical skills required in the industry [9] - Companies are reducing campus recruitment due to the high costs associated with training inexperienced hires [9] Flexible Employment Trends - More pharmaceutical companies are adopting flexible employment models, such as outsourcing and project-based hiring, to maintain operational agility and reduce costs [10][11] - Human resource service providers are encouraged to adapt to these trends by enhancing operational efficiency and offering flexible staffing solutions [11] Future Outlook - The "small but precise" recruitment strategy is expected to continue as pharmaceutical companies optimize their operations in response to market conditions [12]

Core Insights - The overall activity level of the A-share merger and acquisition market in China has slightly decreased, characterized by high frequency, diverse participants, and broad sectors [1] - A total of 80 merger and acquisition events were disclosed during the period, with a total transaction amount of 601.88 billion RMB, showing a significant increase in both the number and value of major M&A events compared to the previous period [2] - The real estate management and development, other metals and mining, semiconductor products, electronic equipment, instruments and components, electrical equipment, and automotive parts sectors are particularly active in M&A activities [2][3] - Private enterprises and local state-owned enterprises are actively engaging in horizontal integration and strategic cooperation, indicating diverse motivations for mergers and acquisitions [1][2] - The M&A market is expected to further release integration and value reconstruction potential, supported by regulatory policy optimization, economic recovery, policy encouragement, and capital market reforms [1] M&A Market Overview - The number of major M&A events in the A-share market increased by 60% compared to the previous period, with a total disclosed transaction amount of 601.88 billion RMB, representing a 187.97% increase [2] - Key sectors for M&A activities include real estate management and development, other metals and mining, semiconductor products, electronic equipment, instruments and components, electrical equipment, and automotive parts [2] - The market is entering a new phase characterized by "efficiency improvement + structural optimization," driven by policy and proactive corporate adjustments [2] Listed Companies' M&A Plans - A total of 44 listed companies announced or planned M&A activities, with an average stock price fluctuation of 7.53% over two weeks [2] - 22 companies made significant progress after announcing M&A plans, with an average stock price fluctuation of 3.76% [2] - The number of major restructuring events increased by 60% compared to the previous period, with research enthusiasm rising by 11.54% [2] Companies with Significant Progress - Companies such as Yunnan Cheng Investment and AnYuan Coal Industry have made notable advancements in their M&A plans, with various strategic objectives including asset adjustments and diversification [10][11] - The progress of these companies reflects a broader trend of active restructuring and strategic realignment within the A-share market [10][11] Market Sentiment and Performance - The restructuring index showed a fluctuation of 5.10% over the two-week period, indicating a positive sentiment in the M&A market [12] - The average price-to-earnings (PE) ratios and market values of companies involved in M&A activities vary significantly, reflecting diverse market conditions and investor sentiments [7][8]